BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15151948)

  • 1. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
    Winegarden JD; Mauer AM; Otterson GA; Rudin CM; Villalona-Calero MA; Lanzotti VJ; Szeto L; Kasza K; Hoffman PC; Vokes EE; ;
    Ann Oncol; 2004 Jun; 15(6):915-20. PubMed ID: 15151948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
    Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
    Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
    Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer.
    Laohavinij S; Maoleekoonpairoj S; Cheirsilpa A; Maneechavakajorn J; Sirachainant E; Arpornvivat W; Jaisathaporn K; Ratanatharathorn V
    Lung Cancer; 1999 Dec; 26(3):175-85. PubMed ID: 10598928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC).
    Chen CH; Chang WC; Lin MC; Hsu JW; Chao TY; Tsao TC
    Lung Cancer; 2002 Oct; 38(1):91-6. PubMed ID: 12367799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study.
    Monnet I; de CH; Soulié P; Saltiel-Voisin S; Bekradda M; Saltiel JC; Brain E; Rixe O; Yataghene Y; Misset JL; Cvitkovic E
    Ann Oncol; 2002 Jan; 13(1):103-7. PubMed ID: 11863089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
    Zhang K; Qin H; Pan F; Liu E; Liang H; Ruan Z
    Med Sci Monit; 2014 Dec; 20():2830-6. PubMed ID: 25548985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.
    Sakai H; Yoneda S; Tamura T; Nishiwaki Y; Yokoyama A; Watanabe K; Saijo N
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):499-503. PubMed ID: 11800032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
    Murren JR; Andersen N; Psyrri D; Brandt D; Nadkarni R; Rose M; Davies MJ; Parisot N; Rosenfield AT; Pizzorno G; Zelterman D
    Cancer Biol Ther; 2005 Dec; 4(12):1311-5. PubMed ID: 16258263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
    Kosmas C; Tsavaris NB; Polyzos A; Kalofonos HP; Sepsas E; Malamos NA; Vadiaka M; Dosios T; Antonopoulos MJ
    Cancer; 2000 Aug; 89(4):774-82. PubMed ID: 10951340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
    Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.